aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extrahepatic Bile Duct Cancer
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Trial Timeline
Aug 1, 2006 → Aug 1, 2012
NCT ID
NCT01534637About aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil
aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil is a phase 2 stage product being developed by Merck for Extrahepatic Bile Duct Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01534637. Target conditions include Extrahepatic Bile Duct Cancer, Nausea, Vomiting.
What happened to similar drugs?
0 of 1 similar drugs in Extrahepatic Bile Duct Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01534637 | Phase 2 | Completed |
Competing Products
4 competing products in Extrahepatic Bile Duct Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 42 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 32 |